ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1806

A Novel Angiopoetin2/TEK Tyrosine Kinase Receptor Mediated Effect On Leukocyte Cell Influx and Oxidative Damage in Inflammatory Arthritis

Emese Balogh1, Chin T. Ng1, Douglas J. Veale2, Ursula Fearon1 and Monika Biniecka1, 1Rheumatology, Translation Research Group, Dublin Academic Medical Centre, St. Vincent's University Hospital, Dublin, Ireland, 2Rheumatology, St. Vincent's University Hospital, Dublin 4, Ireland

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: Angiogenesis, angiopoietin and inflammatory arthritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Cytokines, Mediators, and Gene Regulation

Session Type: Abstract Submissions (ACR)

Background/Purpose:

The Angiopoietin2 (Ang2)/TEK Tyrosine Kinase Receptor (Tie2) signalling pathway acts synergistically with VEGF/flk as critical regulators of new vessel growth, morphology and stability possibly through TNFα sensitization. The aim of this study was to assess the synovial tissue levels of VEGF, Ang2 and Tie2 in inflammatory arthritis patients and examine the effect of TNF inhibitors (TNFi) on VEGF expression and angiopoietin/Tie2 signaling. Moreover we correlated these data with changes in clinical outcomes, hypoxia and oxidative damage.

Methods:

Forty four patients with inflammatory arthritis (RA n=30 and PsA n=14) underwent needle arthroscopy. All subjects had actively inflamed knee joints and were assessed pre-TNFi treatment, with a subgroup (n=20) pre/post TNFi therapy. All patients underwent full assessment including DAS28-CRP, macroscopic vascularity/synovitis, synovial biopsy and in vivo tissue pO2 (tpO2) was measured using a novel LICOX probe. Immunohistology and dual-immunofluorescence were used to quantify vascular factors (VEGF, Ang2 and Tie2), cell specific markers (CD3, CD68) and markers of oxidative damage (8-oxo-dG and 4HNE). 

Results:

At baseline the mean synovial tissue pO2 (tpO2) level was profoundly hypoxic at 25.9 mmHg, equivalent to an ambient oxygen tension 3.4%. VEGF, Ang2 and Tie2 were expressed throughout the synovium localised in the lining layer, sub-lining and vascular regions. VEGF expression correlated with macroscopic synovitis (r=0.41, p=0.031) and vascularity (r=0.40, p=0.034). High Ang2 expression was associated with greater synovitis (r=0.56, p=0.013) and number of CD68+ cells (r=0.53, p=0.013). Tie2 expression was significantly associated with CD3+ cells (r=0.39, p=0.023) and CD68+ cells (r=0.46, p=0.010) and with high ESR and CRP (both r=0.37, p=0.047). Treatment with TNFi showed a significant reduction in expression of Tie2 (p=0.034) and Ang2 (p=0.021) and this was paralleled by an increase in tpO2 levels from mean 22.8 mmHg to 30.3 mmHg. Finally, a significant association between increased ΔVEGF, ΔAng2 and ΔTie2 with high DNA damage (Δ8-oxo-dG) and lipid peroxidation (Δ4-HNE) was demonstrated (both r>0.53, p<0.05), strongly suggesting an interplay between oxidative stress and angiogenesis in a progression of chronic inflammatory arthritis.

Conclusion:

This data suggests that the Ang2/Tie2 signalling pathways may mediate in part the downstream effects of TNF blockade. Furthermore, this is the first evidence to suggest that Ang2/Tie2 maybe directly involved in leukocyte cell influx regulation and oxidative damage within the inflamed joint.


Disclosure:

E. Balogh,
None;

C. T. Ng,
None;

D. J. Veale,

,

,

,

,

;

U. Fearon,
None;

M. Biniecka,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/a-novel-angiopoetin2tek-tyrosine-kinase-receptor-mediated-effect-on-leukocyte-cell-influx-and-oxidative-damage-in-inflammatory-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology